- Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC - SCHAUMBURG, Ill. and IRVINE, Calif., May 01 ...
Fox Chase Cancer Center researchers reported positive results from the trial, known as RETAIN-2, demonstrating that a response-adapted bladder-preservation approach involving neoadjuvant ...
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...
Bladder cancer arises from the lining of the bladder, the organ that stores urine, and is one of the most common cancers in the United States. Most patients are diagnosed at an early stage called ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...
- Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC - Saum Ghodoussipour, M.D., Rutgers Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results